Radar on Specialty Pharmacy

Community Oncology Practices Are Feeling Pandemic Pressure

Community oncology practices already have been hit hard for a number of years, and the COVID-19 pandemic may make the situation worse. But as hospitals try to keep immune-compromised people out, this could result in...
0 Comments

New FDA Specialty Approvals

✦ May 29: The FDA expanded the label of Eli Lilly and Co.’s Cyramza (ramucirumab) to include, in combination with erlotinib, the first-line treatment of people with metastatic non-small cell lung cancer with EGF...
0 Comments

News Briefs

✦ A federal circuit court ruled July 6 that Amgen Inc. gave adequate notice to Roche Group unit Genentech USA, Inc. before commercializing its Mvasi (bevacizumab-awwb), a biosimilar to Genentech’s Avastin (bevac...
0 Comments

COVID Will Transform Cancer Care for Patients and Providers

With the novel coronavirus putting immunocompromised people in particular at risk and hospitals focusing on treating people with COVID-19, many people with cancer are experiencing disruptions in their treatment. And...
0 Comments

Study Shows High Adherence in People on CDK 4/6 Inhibitors

Since 2015, three cyclin-dependent kinase (CDK) 4/6 inhibitors have come onto the U.S. market as treatments for hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or me...
0 Comments

CMS OKs Copay Accumulators For Drugs With No Generics

In a reverse course from its stance a year ago, CMS recently finalized a rule allowing nongrandfathered individual and group market plans to not count manufacturer copayment assistance toward members’ annual deduc...
0 Comments

Questions Surround Some DMD Drugs; More Near U.S. Market

Since 2016, the FDA has approved a handful of therapies to treat Duchenne muscular dystrophy (DMD). But some uncertainty exists over their effectiveness, in addition to concerns about their costs. Additional product...
0 Comments

Source: Pandemic Poses ‘Major Disruption’ to My Cancer Care

A longtime pharma industry expert spoke with AIS Health about their experience as someone with cancer during a pandemic. They asked to remain unidentified: AIS Health: What kind of cancer do you have, and when we...
0 Comments

New FDA Specialty approvals

✦ May 6: The FDA gave accelerated approval to Novartis Pharmaceuticals Corp.’s Tabrecta (capmatinib) for adults with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesen...
0 Comments

News Briefs

✦ The Association for Accessible Medicines (AAM) filed an amicus brief May 13 in support of the Biologics Price Competition and Innovation Act of 2009 (BPCIA) remaining law if the Affordable Care Act (ACA) is inva...
0 Comments